The 70-gene test could aid clinicians and patients in determining the optimal treatment course for breast cancer patients with a very low risk of death from the disease.
We spoke with Mrinal M. Gounder, MD, about next-generation sequencing for sarcoma, and how it can be used to inform treatment decisions and prognosis.
ODAC approval of Novartis' CAR T-Cell therapy paves the way for its FDA approval as a commercially available treatment for B-cell ALL.
RNA splicing variants were found to be critical drivers of prostate cancer aggressiveness and therapeutic resistance in African American men.
Using sticky nanoparticles, researchers have discovered a strategy to improve the immune system's detection of cancer proteins in order to optimize the effectiveness of immunotherapy.
Researchers have discovered a way to test for multiple neuroblastoma-associated genes simultaneously, which may help to improve definition of disease status in patients with relapsed/refractory neuroblastoma.
A new study in JCO suggests that genetic variations within AML patients with CD33 may predict their response to gemtuzumab ozogamicin.
Men with prostate cancer and one additional primary cancer may harbor a mutation in a cancer-predisposing gene, but the majority of these men do not meet criteria for clinical genetic testing.
A follow-up analysis of the CheckMate-205 clinical trial found that nivolumab was associated with durable response rates in adults with relapsed or refractory Hodgkin lymphoma after ASCT.
Newly analyzed data revealed eight gene loci associated with testicular cancer risk that were not previously known.
Neural stem cell therapy combined with a common cold virus may be a highly effective way of improving outcomes in patients with newly diagnosed malignant gliomas.
A subpopulation of T cells called tissue resident memory cells may be able to determine which cancer patients' immune systems can mount an effective anti-tumor response
A new clinical trial is recruiting to determine whether a breath testing device can aid in the diagnosis of breast cancer.
An FLT3 inhibitor, gilteritinib, has been found to result in more frequent and sustained responses in patients with relapsed, refractory acute myeloid leukemia.
The FDA has approved dabrafenib in combination with trametinib for the treatment of BRAF V600E mutated non-small cell lung cancer.